C2N Diagnostics said it will expand in St. Louis, investing millions of dollars and preparing for significant hiring. The company’s expansion includes the relocation of its headquarters and tripling the size of its operations.
C2N will relocate its headquarters and expand its federally regulated CAP accredited-CLIA certified lab operation. Washington University is redeveloping the former Goodwill Industries International site. C2N’s new lab at Catalyst will leverage the latest advancements in bioautomation and high-resolution, high-throughput proteomic testing. Altogether, C2N will occupy 82,451 new square feet at the new site, filling the first three floors. C2N expects to begin the move in late 2026.
C2N is best known for commercializing the first clinical blood test for Alzheimer’s disease and more recently for its highly accurate PrecivityAD2 blood test, which helps health care professionals in the detection of amyloid plaques in the brain. Amyloid plaques are a pathological hallmark of Alzheimer's disease and inform medical management and treatment decisions.
In addition to the new headquarters, C2N will maintain its existing lab facility and turn it into a center dedicated to providing cutting-edge multi-omic solutions and advanced analytical platforms. The center will help drive innovation across its biopharmaceutical research services, medtech business units, and international collaborative research initiatives.
